Simcere Pharmaceutical Group Limited

SEHK:2096 Stock Report

Market Cap: HK$16.7b

Simcere Pharmaceutical Group Future Growth

Future criteria checks 3/6

Simcere Pharmaceutical Group is forecast to grow earnings and revenue by 71.5% and 1.8% per annum respectively. EPS is expected to grow by 71.3% per annum. Return on equity is forecast to be 15.4% in 3 years.

Key information

71.5%

Earnings growth rate

71.3%

EPS growth rate

Pharmaceuticals earnings growth10.6%
Revenue growth rate1.8%
Future return on equity15.4%
Analyst coverage

Low

Last updated06 Feb 2025

Recent future growth updates

Recent updates

Simcere Pharmaceutical Group Limited's (HKG:2096) P/S Still Appears To Be Reasonable

Nov 21
Simcere Pharmaceutical Group Limited's (HKG:2096) P/S Still Appears To Be Reasonable

Simcere Pharmaceutical Group Limited (HKG:2096) Not Lagging Market On Growth Or Pricing

Jul 29
Simcere Pharmaceutical Group Limited (HKG:2096) Not Lagging Market On Growth Or Pricing

Why Simcere Pharmaceutical Group's (HKG:2096) Shaky Earnings Are Just The Beginning Of Its Problems

May 01
Why Simcere Pharmaceutical Group's (HKG:2096) Shaky Earnings Are Just The Beginning Of Its Problems

Simcere Pharmaceutical Group Limited's (HKG:2096) Business And Shares Still Trailing The Market

Dec 29
Simcere Pharmaceutical Group Limited's (HKG:2096) Business And Shares Still Trailing The Market

Need To Know: Analysts Just Made A Substantial Cut To Their Simcere Pharmaceutical Group Limited (HKG:2096) Estimates

Aug 28
Need To Know: Analysts Just Made A Substantial Cut To Their Simcere Pharmaceutical Group Limited (HKG:2096) Estimates

Are Investors Undervaluing Simcere Pharmaceutical Group Limited (HKG:2096) By 40%?

Jun 03
Are Investors Undervaluing Simcere Pharmaceutical Group Limited (HKG:2096) By 40%?

Analysts Just Shaved Their Simcere Pharmaceutical Group Limited (HKG:2096) Forecasts Dramatically

Apr 06
Analysts Just Shaved Their Simcere Pharmaceutical Group Limited (HKG:2096) Forecasts Dramatically

Estimating The Intrinsic Value Of Simcere Pharmaceutical Group Limited (HKG:2096)

Jan 10
Estimating The Intrinsic Value Of Simcere Pharmaceutical Group Limited (HKG:2096)

With EPS Growth And More, Simcere Pharmaceutical Group (HKG:2096) Makes An Interesting Case

Aug 16
With EPS Growth And More, Simcere Pharmaceutical Group (HKG:2096) Makes An Interesting Case

Simcere Pharmaceutical Group (HKG:2096) Has Announced A Dividend Of HK$0.18

Jun 27
Simcere Pharmaceutical Group (HKG:2096) Has Announced A Dividend Of HK$0.18

Earnings and Revenue Growth Forecasts

SEHK:2096 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20268,7771,4747061,5415
12/31/20257,7261,2596089315
12/31/20246,7349438221,2665
6/30/20246,340-1,1022401,096N/A
3/31/20246,474-194-294623N/A
12/31/20236,608715-829151N/A
9/30/20236,8081,927-504369N/A
6/30/20237,0063,141-179587N/A
3/31/20236,6652,036249971N/A
12/31/20226,3249316761,354N/A
9/30/20225,9529726731,180N/A
6/30/20225,5791,0136711,006N/A
3/31/20225,2901,260130402N/A
12/31/20215,0001,507-411-202N/A
9/30/20214,8521,274-481-200N/A
6/30/20214,7031,042-551-198N/A
3/31/20214,606856-404-51N/A
12/31/20204,509670-25697N/A
9/30/20204,528699-314-6N/A
6/30/20204,548728-371-109N/A
3/31/20204,792866-53332N/A
12/31/20195,0371,004265773N/A
12/31/20184,514734441776N/A
12/31/20173,868350N/A939N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2096 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Earnings vs Market: 2096 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 2096 is expected to become profitable in the next 3 years.

Revenue vs Market: 2096's revenue (1.8% per year) is forecast to grow slower than the Hong Kong market (7.7% per year).

High Growth Revenue: 2096's revenue (1.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 2096's Return on Equity is forecast to be low in 3 years time (15.4%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 10:33
End of Day Share Price 2025/02/07 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Simcere Pharmaceutical Group Limited is covered by 16 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sharon ShiBOCI Research Ltd.
Shaojing TongBofA Global Research
Bo YuChina International Capital Corporation Limited